Panel

Sara Tolaney, MD, MPH
Associate Director, Susan F. Smith Center for Women’s Cancers
Director, Clinical Trials, Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School

Bhuvaneswari Ramaswamy, MD, MRCP
Professor and Section Chief- Breast Medical Oncology
The Ohio State University Comprehensive Cancer Center
In this month's journal scan, our panel reviews:
- Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer
- Biomarker Evaluation in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients With Metastatic Triple-Negative Breast Cancer
- First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)